Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(12), P. 1604 - 1604
Published: Dec. 16, 2024
This
review
aims
to
examine
existing
research
on
the
development
of
ocular
drug
delivery
devices
utilizing
hyaluronic
acid
(HA).
Renowned
for
its
exceptional
biocompatibility,
viscoelastic
properties,
and
ability
enhance
bioavailability,
HA
is
a
naturally
occurring
biopolymer.
The
discussed
specific
mechanisms
by
which
enhances
delivery,
including
prolonging
residence
time
surfaces,
facilitating
controlled
release,
improving
penetration
through
tissues.
By
focusing
these
unique
functionalities,
this
highlights
potential
HA-based
systems
revolutionize
treatment.
Various
fabrication
techniques
systems,
hydrogels,
nanoparticles,
microneedles,
are
discussed,
highlighting
their
respective
advantages
limitations.
Additionally,
explores
clinical
applications
in
treating
range
diseases,
such
as
dry
eye
syndrome,
glaucoma,
retinal
disorders,
infections.
comparing
efficacy
safety
profiles
with
traditional
methods,
provide
comprehensive
understanding
benefits
challenges
associated
systems.
Moreover,
discusses
current
limitations
future
directions
field,
need
standardized
protocols,
long-term
biocompatibility
studies,
large-scale
trials.
insights
advancements
presented
aim
guide
efforts,
ultimately
enhancing
effectiveness
patient
outcomes.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(17), P. 9190 - 9190
Published: Aug. 24, 2024
CD44
regulates
cell
adhesion,
proliferation,
survival,
and
stemness
has
been
considered
a
tumor
therapy
target.
possesses
the
shortest
standard
(CD44s)
variety
of
variant
(CD44v)
isoforms.
Since
expression
CD44v
is
restricted
in
epithelial
cells
carcinomas
compared
to
CD44s,
promising
target
for
monoclonal
antibody
(mAb)
therapy.
We
previously
developed
an
anti-CD44v10
mAb,
C
CD44
is
a
type
I
transmembrane
glycoprotein,
which
associated
with
poor
prognosis
in
various
solid
tumors.
Since
plays
critical
roles
tumor
development
by
regulating
cell
adhesion,
survival,
proliferation,
and
stemness,
it
has
been
considered
target
for
therapy.
Anti-CD44
monoclonal
antibodies
(mAbs)
have
developed
applied
to
antibody-drug
conjugates
chimeric
antigen
receptor-T
We
previously
anti‐pan-CD44
mAbs,
C44Mab-5
C44Mab-46,
can
recognize
both
standard
(CD44s)
variant
isoforms.
In
the
present
study,
defucosylated
mouse
IgG2a
version
of
anti-pan-CD44
mAbs
(5-mG2a-f
C44Mab-46-mG2a-f)
was
generated
evaluate
antitumor
activities
against
CD44-positive
cells.
Both
5-mG2a-f
C44Mab-46-mG2a-f
recognized
CD44s-overexpressed
CHO-K1
(CHO/CD44s)
cells
esophageal
line
(KYSE770)
flow
cytometry.
Furthermore,
could
activate
effector
presence
CHO/CD44s
exhibited
complement‐dependent
cytotoxicity
KYSE770
administration
significantly
suppressed
xenograft
compared
control
IgG2a.
These
results
indicate
that
exert
cancers
be
promising
therapeutic
regimen
Biotechnology and Applied Biochemistry,
Journal Year:
2024,
Volume and Issue:
71(5), P. 1154 - 1163
Published: May 29, 2024
Abstract
Interventional
chemotherapy
is
a
common
operation
in
the
clinical
treatment
of
liver
cancer.
The
aim
this
study
was
to
investigate
expression
and
molecular
mechanism
serum
miR‐4746‐5p
cancer
patients
before
after
interventional
chemotherapy.
levels
CDKN1C
samples
from
were
detected
using
real‐time
fluorescence
quantitative
polymerase
chain
reaction.
Receiver
operating
characteristic
curves
revealed
diagnostic
value
tumors.
Differences
indicators
between
healthy
controls
assessed
Pearson
correlation
analysis.
Luciferase
reporter
gene
assays
confirmed
targeted
interaction
CDKN1C.
In
vitro
cellular
validated
by
Cell
Counting
Kit‐8,
Transwell
assay,
chemoresistance
assay.
Serum
increased
but
downregulated
intervention.
showed
opposite
trend.
Low
mediated
cell
growth
metastasis
targeting
negatively
regulating
expression,
while
silencing
restored
activity.
Inhibition
reduced
chemoresistance,
downregulation
affected
sensitivity.
may
be
potential
therapeutic
factor
for
diagnosis
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Nov. 28, 2024
Distant
metastasis
is
the
leading
cause
of
cancer-related
mortality,
and
achieving
survival
benefits
through
advancements
in
systemic
therapy
remains
challenging.
Mast
cells
play
a
dual
role
shaping
tumor
microenvironment
(TME)
influencing
distant
metastasis,
underscoring
significant
research
value
targeting
mast
for
advanced
cancer.
We
investigated
variations
cell
infiltration
levels
primary
metastatic
malignancies
using
immunocyte
analysis.
subsets
were
identified
from
pan-cancer
single-cell
sequencing
data
dimensionality
reduction
clustering
type
annotation,
combined
with
trajectory
communication
network
analyses.
A
prognostic
model
was
established
WGCNA
12
machine
learning
algorithms
to
identify
potential
targets.
Drug
sensitivity
Mendelian
randomization
analyses
conducted
select
drugs
cells,
their
effects
on
epithelial-mesenchymal
transition
(EMT)
validated
vitro
experiments,
including
wound
healing,
transwell,
western
blot
assays.
Results
revealed
that
activated
show
increased
tumors,
correlating
poor
duration.
XBP1+
as
key
components
inhibitory
TME,
potentially
involved
EMT
activation.
Simvastatin
drug,
reversing
induced
by
pan-cancer.
Aberrant
activation
MEK/ERK
signaling
can
stimulate
cancer
modulating
degranulation,
while
inhibit
suppressing
degranulation.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(12), P. 1604 - 1604
Published: Dec. 16, 2024
This
review
aims
to
examine
existing
research
on
the
development
of
ocular
drug
delivery
devices
utilizing
hyaluronic
acid
(HA).
Renowned
for
its
exceptional
biocompatibility,
viscoelastic
properties,
and
ability
enhance
bioavailability,
HA
is
a
naturally
occurring
biopolymer.
The
discussed
specific
mechanisms
by
which
enhances
delivery,
including
prolonging
residence
time
surfaces,
facilitating
controlled
release,
improving
penetration
through
tissues.
By
focusing
these
unique
functionalities,
this
highlights
potential
HA-based
systems
revolutionize
treatment.
Various
fabrication
techniques
systems,
hydrogels,
nanoparticles,
microneedles,
are
discussed,
highlighting
their
respective
advantages
limitations.
Additionally,
explores
clinical
applications
in
treating
range
diseases,
such
as
dry
eye
syndrome,
glaucoma,
retinal
disorders,
infections.
comparing
efficacy
safety
profiles
with
traditional
methods,
provide
comprehensive
understanding
benefits
challenges
associated
systems.
Moreover,
discusses
current
limitations
future
directions
field,
need
standardized
protocols,
long-term
biocompatibility
studies,
large-scale
trials.
insights
advancements
presented
aim
guide
efforts,
ultimately
enhancing
effectiveness
patient
outcomes.
